Ovarian reserve testing typically involves a simple blood draw, an ultrasound, or both. The most common approach combines a blood test for anti-Müllerian hormone (AMH) with a transvaginal ultrasound to count small follicles on the ovaries. Some providers also check follicle-stimulating hormone (FSH) and estradiol levels early in the menstrual cycle. None of these tests require surgery or sedation, and most results come back within a few days.
The AMH Blood Test
AMH is the most widely used single marker of ovarian reserve. It’s produced by the cells surrounding small, growing follicles in the ovary, so the amount circulating in your blood reflects how many of those developing follicles you have at any given time. It doesn’t directly measure your total pool of dormant eggs, but it serves as the best available proxy for that number, especially as you get older.
The practical appeal of AMH testing is its flexibility. Unlike other hormone tests, AMH levels stay relatively stable throughout your menstrual cycle, so the blood draw can happen on any day. You don’t need to fast beforehand either. Research comparing fasting and non-fasting blood samples found no significant difference in AMH concentrations. A standard blood draw from your arm is all that’s needed.
One thing to be aware of: if you’re currently on hormonal birth control, your AMH level may read about 30% lower than it actually is. If your result comes back surprisingly low while you’re on the pill, your provider may recommend retesting after you’ve been off hormonal contraception for a cycle or two.
What AMH Numbers Mean
AMH is measured in nanograms per milliliter (ng/mL). General reference ranges look like this:
- Average: 1.0 to 3.0 ng/mL
- Low: Under 1.0 ng/mL
- Severely low: Around 0.4 ng/mL
Because AMH naturally declines with age, the same number means different things at different points in life. A level of 3.0 ng/mL is on the lower end of normal for a 25-year-old, while 1.0 ng/mL is typical for someone around 40. By age 45, the average drops to about 0.5 ng/mL. Your provider will interpret your result in the context of your age and overall health picture rather than relying on a single cutoff.
The Antral Follicle Count
An antral follicle count (AFC) uses transvaginal ultrasound to visually count the small, fluid-filled follicles sitting on both ovaries. The technician or doctor inserts a slim ultrasound probe and scans from one edge of each ovary to the other, counting every follicle that measures between 2 and 10 millimeters in diameter. Anything smaller than 2 mm or larger than 10 mm is excluded from the count.
This is usually done early in the menstrual cycle, around days 2 through 5, when the follicles are easiest to see and measure before one becomes dominant. The scan takes only a few minutes. It can feel similar to a pelvic exam, with mild pressure but generally no significant pain. Combined with AMH, the AFC gives a more complete picture of ovarian reserve than either test alone.
FSH and Estradiol Testing
FSH and estradiol are older ovarian reserve markers that some providers still use, often alongside AMH. Unlike AMH, these hormones fluctuate significantly during your cycle, so the timing of the blood draw matters. The sample is typically drawn on day 3 of your menstrual cycle (day 1 being the first full day of your period). Days 2, 4, or 5 are acceptable but day 3 is preferred.
FSH is the hormone your brain releases to tell the ovaries to develop a follicle each month. When fewer follicles remain, the brain has to send a louder signal, so FSH levels rise. Based on World Health Organization standards, an FSH level under 10 mIU/mL is considered normal, levels above 11.4 are moderately high, and anything over 16.7 is high. Estradiol is usually drawn at the same time because an elevated estradiol level early in the cycle can artificially suppress FSH, making a high reading look falsely normal.
What These Tests Can and Cannot Tell You
This is where many people run into confusion. Ovarian reserve tests measure quantity, not quality, of your remaining eggs. They’re reliable predictors of how your ovaries will respond to fertility medications during IVF. A higher AMH and AFC generally means more eggs can be retrieved during a stimulation cycle, which gives more opportunities for a viable embryo.
What these tests do not predict well is your ability to conceive naturally. Research consistently shows that AMH has no meaningful predictive value for pregnancy or live birth in women who are otherwise fertile. The same is true for AFC. In one study comparing IVF outcomes in women with AMH levels above and below 1.1 ng/mL, live birth rates were 25.85% and 22.22% respectively, a difference that was not statistically significant. The American Society for Reproductive Medicine explicitly states that ovarian reserve markers should not be used as a fertility test for women who are not infertile or who have untested fertility.
In practical terms, this means a low AMH result does not mean you can’t get pregnant on your own, and a normal result doesn’t guarantee that you can. These tests are most useful when you’re already working with a fertility specialist and need to plan a treatment strategy.
Who Should Get Tested
Ovarian reserve testing is most commonly recommended for women over 35 who have been trying to conceive for six months without success, women over 40 regardless of how long they’ve been trying, and anyone with risk factors for a diminished egg supply. Those risk factors include a family history of early menopause, previous ovarian surgery, chemotherapy or radiation exposure, and unexplained infertility.
Testing is also standard before IVF or egg freezing, where knowing your likely response to stimulation medications directly shapes the treatment protocol. Some women in their late 20s or early 30s request testing proactively to inform decisions about family planning timelines. While the results can offer useful context, they should be interpreted carefully, given the limitations around predicting natural fertility.
Tests That Have Fallen Out of Use
You may come across references to the clomiphene citrate challenge test (CCCT), which involved taking a fertility drug for five days and measuring FSH before and after. This test added complexity without offering much more information than a simple day-3 FSH, and it has largely been replaced by AMH and AFC testing, which are simpler, more reliable, and less burdensome for patients. If your provider suggests only AMH and an ultrasound, that reflects current best practice.